Month: December 2019

In a recent article, I discussed the rise of targeted protein degradation (TPD) therapeutics and the surge in big pharma interest in this emerging space. With more than 3,600 tweets posted over the last three years to over 5,000 articles published over the last decade, the concept of targeted protein degradation has got the right

When a big pharma agrees to spend millions in acquiring a drug discovery company, the world is bound to take note. The same happened earlier this year – the acquisition of Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) was a piece of big news in the drug discovery world, validating the potential of DNA